UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 31, 2015

 

 

IMMUNE PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)

 

Delaware 001-36602 52-1841431

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

430 East 29th Street, Suite 940, New York, NY 10016
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code:  (646) 440-9310

 

N/A
(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
x Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

        

 

 

  

Item 8.01. Other Events.

 

On August 31, 2015, Immune Pharmaceuticals Inc. (the “Company”) convened a Special Meeting of Stockholders (the “Special Meeting”) and adjourned for lack of quorum to conduct formal business. The Special Meeting was adjourned until 2:00 p.m., local time, on September 24, 2015 to be held at the Company’s headquarters located at 430 East 29th Street, Suite 940, New York, NY 10016. The meeting was adjourned to provide the Company with additional time to solicit proxies from its stockholders to establish the requisite quorum for the conduct of formal business at the Special Meeting. The record date for the Special Meeting has not changed. Only stockholders of record at the close of business on July 29, 2015 are entitled to vote at the reconvened Special Meeting.

 

During the period of the adjournment, the Company will continue to solicit proxies from its stockholders with respect to the proposals set forth in the Company's proxy statement. Proxies previously submitted in respect of the Special Meeting will be voted at the adjourned meeting unless properly revoked.

 

The Company encourages all stockholders who have not yet voted to do so before September 23, 2015 at 11.59 p.m. EDT.

 

No changes have been made in the proposals to be voted on by stockholders at the Special Meeting. The Company's proxy statement and any other materials filed by the Company with the SEC remain unchanged and can be obtained free of charge at the SEC's website at www.sec.gov.

 

 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMMUNE PHARMACEUTICALS INC.
   
Dated: August 31, 2015 By:

/s/ Daniel G. Teper

    Name:  Daniel G. Teper
    Title: Chief Executive Officer